Update in Imaging Evaluation of Bone and Soft Tissue Sarcomas.

Rev Bras Ortop (Sao Paulo)

Departamento de Radiologia, Universidade Federal Fluminense, Niterói, RJ, Brasil.

Published: April 2023

The evolution in imaging evaluation of musculoskeletal sarcomas contributed to a significant improvement in the prognosis and survival of patients with these neoplasms. The precise characterization of these lesions, using the most appropriate imaging modalities to each clinical condition presented, is of paramount importance in the design of the therapeutic approach to be instituted, with a direct impact on clinical outcomes. The present article seeks to update the reader regarding imaging methodologies in the context of local and systemic evaluation of bone sarcomas and soft tissues.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212631PMC
http://dx.doi.org/10.1055/s-0041-1736569DOI Listing

Publication Analysis

Top Keywords

imaging evaluation
8
evaluation bone
8
update imaging
4
bone soft
4
soft tissue
4
tissue sarcomas
4
sarcomas evolution
4
evolution imaging
4
evaluation musculoskeletal
4
musculoskeletal sarcomas
4

Similar Publications

White Matter Fiber Bundle Alterations Correlate with Gait and Cognitive Impairments in Parkinson's Disease based on HARDI Data.

Curr Med Imaging

January 2025

Department of Radiology, Beijing Friendship Hospital, Capital Medical University, No. 95, Yong An Road, Xicheng District, Beijing 100050, China.

Background: The neuroanatomical basis of white matter fiber tracts in gait impairments in individuals suffering from Parkinson's Disease (PD) is unclear.

Methods: Twenty-four individuals living with PD and 29 Healthy Controls (HCs) were included. For each participant, two-shell High Angular Resolution Diffusion Imaging (HARDI) and high-resolution 3D structural images were acquired using the 3T MRI.

View Article and Find Full Text PDF

Background: Lenvatinib is an oral tyrosine kinase inhibitor that selectively inhib-its receptors involved in tumor angiogenesis and tumor growth. It is an emerging first-line treatment agent for hepatocellular carcinoma (HCC). However, there is no intravenous ad-ministration of Lenvatinib.

View Article and Find Full Text PDF

Therapeutic hurdles persist in the fight against lung cancer, although it is a leading cause of cancer-related deaths worldwide. Results are still not up to par, even with the best efforts of conventional medicine, thus new avenues of investigation are required. Examining how immunotherapy, precision medicine, and AI are being used to manage lung cancer, this review shows how these tools can change the game for patients and increase their chances of survival.

View Article and Find Full Text PDF

Aims: This study aimed to develop Imatinib Mesylate (IMT)-loaded Poly Lactic-co-Glycolic Acid (PLGA)-D-α-tocopheryl polyethylene glycol succinate (TPGS)- Polyethylene glycol (PEG) hybrid nanoparticles (CSLHNPs) with optimized physicochemical properties for targeted delivery to glioblastoma multiforme.

Background: Glioblastoma multiforme (GBM) is the most destructive type of brain tumor with several complications. Currently, most treatments for drug delivery for this disease face challenges due to the poor blood-brain barrier (BBB) and lack of site-specific delivery.

View Article and Find Full Text PDF

Crystal Violet (CV) is a vibrant and harmful dye known for its toxicity to aquatic life and potential carcinogenic effects on humans. This study explores the removal of CV through photocatalysis driven by visible light, as well as examining the antibacterial and antibiofilm characteristics of zinc oxide nanoparticles (ZnO NPs) synthesized from the aerial roots of Ficus benghalensis. Various characterization techniques were employed to confirm the optical properties, crystal lattices, and morphology of ZnO NPs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!